Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02605447 · ClinicalTrials.gov registry record · Phase 4
EVOLVE Short DAPT Study
A Phase 4 study of Coronary Artery Disease, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 2,009
- Enrollment target
- 20
- Study locations
NCT02605447: Completed Phase 4 study of Coronary Artery Disease, sponsored by Boston Scientific Corporation.
NCT02605447 is a Phase 4 study of Coronary Artery Disease that has completed, run by Boston Scientific Corporation. The registered enrollment target is 2,009 participants, above the 1,278-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02605447, a Phase 4 study of Coronary Artery Disease, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 2,009 participants
- Enrollment target
- 20
- Study locations
Study Summary
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
Primary Outcome
Rate of death or myocardial infarction
Conditions Studied
Interventions
- DRUG 3 months of dual antiplatelet therapy (DAPT)
- DEVICE SYNERGY Stent System
Study Locations (20)
California
- Bakersfield Memorial Hospital - Bakersfield
- USC Medical Center - Los Angeles
- Cedars - Sinai Medical Center - Los Angeles
- El Camino Hospital - Mountain View
- HCA Riverside Community Hospital - Riverside
- Sutter Medical Center, Sacramento - Sacramento
- University of California, Davis Medical Center - Sacramento
- Kaiser Foundation Hospital - San Francisco - San Francisco
- John Muir Medical Center - Walnut Creek
Florida
- JFK Medical Center - Atlantis
- Morton Plant Mease Healthcare System - Clearwater
- North Florida Regional Medical Center - Gainesville
- Memorial Regional Hospital - Hollywood
Arizona
- Banner Good Samaritan Regional Medical Center - Phoenix
- St. Joseph's Hospital & Medical Center - Phoenix
Arkansas
- Baptist Health Medical Center (Little Rock) - Little Rock
- Arkansas Heart Hospital - Little Rock
Colorado
- South Denver Cardiology Associates, PC - Littleton
Connecticut
- Yale-New Haven Hospital - New Haven
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,009 participants |
| Start Date | 2016-02-16 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 4 |
What the finished NCT02605447 record still lists
NCT02605447 is an interventional study that assigns participants to a tested intervention. Its 2,009 participants enrollment target places it among the larger protocols in the corpus, above the 1,278-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (57% higher).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which 3 months of dual antiplatelet therapy (DAPT) is the first listed.
NCT02605447 names 20 study sites across 7 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02605447 about?
NCT02605447 is a clinical study titled "EVOLVE Short DAPT Study". The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
What is the current status of trial NCT02605447?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 2,009 participants. The study started on 2016-02-16. Estimated completion is 2019-07-17.
What conditions does trial NCT02605447 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT02605447?
The interventions under investigation include: 3 months of dual antiplatelet therapy (DAPT) (DRUG), SYNERGY Stent System (DEVICE).
Who is sponsoring clinical trial NCT02605447?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02605447 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02605447's enrollment target sits among peer trials
2,009 29th of 219 higher than 191 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
RECRUITING · Phase 4
-
The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
RECRUITING · Phase 4
-
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
RECRUITING · Phase 4
-
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
RECRUITING · Phase 4
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
RECRUITING · Phase 4
-
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI